+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cognitive & Memory Enhancer Drugs Market by Application, Mechanism Of Action, Distribution Channel, Dosage Form, End User - Global Forecast to 2030- Product Image
Cognitive & Memory Enhancer Drugs Market by Application, Mechanism Of Action, Distribution Channel, Dosage Form, End User - Global Forecast to 2030- Product Image
Sale

Cognitive & Memory Enhancer Drugs Market by Application, Mechanism Of Action, Distribution Channel, Dosage Form, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904721
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cognitive & Memory Enhancer Drugs Market grew from USD 6.49 billion in 2024 to USD 7.13 billion in 2025. It is expected to continue growing at a CAGR of 9.60%, reaching USD 11.26 billion by 2030.

Unveiling the Promise of Cognitive and Memory Enhancers

The accelerating prevalence of neurodegenerative disorders, coupled with growing demand for enhanced cognitive performance across professions and demographics, has propelled cognitive and memory enhancers into the forefront of pharmaceutical innovation. As populations age and awareness of cognitive health deepens, stakeholders from drug developers to care providers are seeking potent, evidence-based solutions to mitigate memory loss, maintain attentional capacity, and improve overall brain function.

This report delves into the dynamic interplay of scientific breakthroughs, regulatory evolutions, and shifting patient expectations that are reshaping the landscape of cognitive therapeutics. Drawing upon rigorous research and expert insights, we explore how novel mechanisms of action and diversified delivery channels are converging to address unmet needs in Alzheimer’s disease, ADHD, Parkinson’s disease, and general cognitive enhancement. The introduction sets the stage for an in-depth examination of transformative shifts, trade implications, segmentation nuances, regional dynamics, competitive strategies, and actionable recommendations that will guide decision-makers through the complexities of this high-growth domain.

Paradigm Shifts Redefining Cognitive Therapeutics

Recent years have witnessed paradigm-altering developments in neuroscience, digital health, and precision medicine that are redefining the trajectory of cognitive therapeutics. Advances in biomarker validation and neuroimaging have enhanced early detection and patient stratification, enabling tailored interventions that maximize therapeutic efficacy while minimizing adverse events.

In parallel, regulatory agencies have introduced more flexible pathways for breakthrough designations and adaptive licensing, accelerating the time to market for novel compounds. Partnerships between biotech firms and technology providers are fostering the integration of digital therapeutics with pharmacological regimens, enhancing patient adherence and real-time monitoring. These shifts not only expand the scope of treatable conditions but also pave the way for synergistic solutions that address cognitive health holistically, from synaptic modulation to lifestyle interventions.

Tariff Impacts Forge New Trade Realities in 2025

The implementation of revised United States tariff schedules in 2025 has introduced new considerations for manufacturers and distributors of cognitive enhancers. With increased import duties on certain active pharmaceutical ingredients, stakeholders are reevaluating global supply chains to maintain cost competitiveness and ensure uninterrupted production.

Domestic API sourcing has gained prominence as companies pursue vertical integration to mitigate tariff impacts and reduce exposure to trade volatility. These developments are driving strategic investments in local manufacturing capabilities and fostering collaborations with regional suppliers. At the same time, end-to-end logistics solutions are being optimized to navigate evolving customs requirements and streamline cross-border distribution, ultimately safeguarding product availability and price stability for critical cognitive therapies.

Segment Dynamics Illuminate Varied Market Demands

A nuanced understanding of the market emerges when examining distinct segments defined by therapeutic application, mechanism of action, distribution channel, dosage form, and end-user setting. In applications ranging from Alzheimer’s disease to attention deficit hyperactivity disorder, general cognitive enhancement, and Parkinson’s disease, patient populations and clinical objectives vary significantly, driving specialized development and marketing strategies. The mechanisms of action span cholinesterase inhibitors-with key molecules such as donepezil, galantamine, and rivastigmine-through NMDA antagonists exemplified by memantine, to psychostimulants like amphetamines and methylphenidate, and nootropic racetams such as aniracetam and piracetam, each offering unique pharmacodynamic profiles.

Distribution pathways further shape accessibility, with hospital pharmacies serving acute and inpatient needs, online pharmacies enabling remote fulfillment and discreet delivery, and retail pharmacies providing broad community reach. Dosage formats tailored to diverse patient preferences and clinical settings include capsules, injectables, oral powders, and tablets, facilitating both chronic administration regimens and acute symptom management. Finally, clinics, home care environments, and hospitals represent the primary end-user segments, each with distinct procurement frameworks, regulatory considerations, and patient support requirements. Integrating these segmentation dimensions offers a comprehensive lens through which to assess competitive positioning and unmet market needs.

Regional Trajectories Highlight Unique Growth Drivers

The Americas continue to lead in research investment, regulatory innovation, and patient access programs, driven by a strong presence of multinational pharmaceutical entities and established reimbursement mechanisms. In Europe, Middle East & Africa, market growth is shaped by harmonization efforts across the European Medicines Agency and national health authorities, alongside emerging access initiatives in the Middle East and North Africa. Asia-Pacific exhibits rapid expansion, propelled by increasing healthcare expenditure, the rise of generics manufacturing in India, and strategic biotechnology hubs in China and South Korea.

Each region presents unique opportunities and challenges: while North America emphasizes precision medicine and payer-driven value models, EMEA markets balance cost containment with innovative therapy adoption, and Asia-Pacific stakeholders prioritize scalable production, cost-effective delivery, and government-led public health campaigns. Understanding these regional trajectories is essential for tailoring market entry strategies, forging local partnerships, and aligning product portfolios with evolving regulatory and reimbursement landscapes.

Competitive Landscape Shaped by Key Industry Players

A competitive landscape marked by both established pharmaceutical giants and agile biotech innovators underscores the sector’s vibrancy. Leading companies have intensified portfolios through mergers, acquisitions, and licensing deals that expand their presence across cholinesterase inhibitors and NMDA antagonists. Meanwhile, emerging players focus on next-generation psychostimulants and novel racetam analogs, seeking to carve out differentiated niches with proprietary formulations and targeted patient support services.

Partnerships between small-cap biotech firms and contract research organizations are accelerating early-stage pipelines, while alliances with digital health companies are enabling integrated treatment platforms. As market incumbents defend their core franchises, they are simultaneously investing in lifecycle management and indication expansion, setting the stage for competitive dynamics that will hinge on speed to market, clinical differentiation, and the ability to demonstrate real-world outcomes.

Strategic Imperatives to Outpace Market Evolution

To thrive amidst intensifying competition and evolving regulatory frameworks, industry leaders must embrace strategic imperatives that align R&D, commercial, and operational functions. Investing in biomarkers and companion diagnostics will enhance patient stratification and support premium pricing models. Expanding digital health competencies can drive patient engagement, adherence, and data-driven insights that reinforce value propositions with payers.

Diversifying supply chains and establishing resilient manufacturing footprints are critical to mitigating tariff exposures and ensuring product continuity. Engaging proactively with regulators to shape policy on accelerated approvals and adaptive pathways will unlock earlier market access. Finally, implementing customized patient support programs and medical education initiatives will foster brand loyalty and improve outcomes, reinforcing the therapeutic and economic value of cognitive enhancement therapies.

Rigorous Methodology Underpins Robust Insights

The insights presented in this report are grounded in a rigorous, multi-stage research methodology that combines comprehensive secondary research with targeted primary engagements. We conducted in-depth interviews with industry executives, clinical specialists, and regulatory authorities to capture nuanced perspectives on therapeutic trends and market drivers. Secondary sources-including peer-reviewed journals, industry publications, and regulatory filings-were systematically analyzed to validate key findings and ensure data integrity.

Quantitative analyses and data triangulation techniques were applied to synthesize disparate information streams, while iterative reviews with internal subject matter experts provided quality assurance and contextual relevance. This robust approach ensures that our conclusions and recommendations are both credible and actionable, equipping stakeholders with the strategic intelligence needed to navigate the cognitive and memory enhancement landscape.

Synthesis of Trends and Future Outlook

The convergence of scientific innovation, regulatory evolution, shifts in global trade policy, and dynamic market segmentation creates a fertile environment for transformative growth in cognitive and memory enhancement drugs. Stakeholders who integrate these insights-ranging from mechanism-based differentiation and tailored distribution strategies to regional market entry nuances-will be best positioned to capture value in this complex ecosystem.

Our analysis underscores the importance of agility, cross-functional alignment, and patient-centric solutions as the cornerstones of sustained success. By synthesizing these themes and anticipating emerging trends, decision-makers can formulate strategic roadmaps that not only address current market realities but also prepare for the next wave of therapeutic breakthroughs and commercial opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Alzheimer's Disease
    • Attention Deficit Hyperactivity Disorder
    • General Cognitive Enhancement
    • Parkinson's Disease
  • Mechanism Of Action
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Antagonists
      • Memantine
    • Psychostimulants
      • Amphetamines
      • Methylphenidate
    • Racetams
      • Aniracetam
      • Piracetam
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Dosage Form
    • Capsules
    • Injectable
    • Oral Powder
    • Tablets
  • End User
    • Clinics
    • Home Care
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Eisai Co., Ltd
  • AbbVie Inc
  • Johnson & Johnson
  • Pfizer Inc
  • Lundbeck A/S
  • Biogen Inc
  • Eli Lilly and Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cognitive & Memory Enhancer Drugs Market, by Application
8.1. Introduction
8.2. Alzheimer's Disease
8.3. Attention Deficit Hyperactivity Disorder
8.4. General Cognitive Enhancement
8.5. Parkinson's Disease
9. Cognitive & Memory Enhancer Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. Cholinesterase Inhibitors
9.2.1. Donepezil
9.2.2. Galantamine
9.2.3. Rivastigmine
9.3. NMDA Antagonists
9.3.1. Memantine
9.4. Psychostimulants
9.4.1. Amphetamines
9.4.2. Methylphenidate
9.5. Racetams
9.5.1. Aniracetam
9.5.2. Piracetam
10. Cognitive & Memory Enhancer Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Cognitive & Memory Enhancer Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsules
11.3. Injectable
11.4. Oral Powder
11.5. Tablets
12. Cognitive & Memory Enhancer Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Americas Cognitive & Memory Enhancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cognitive & Memory Enhancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cognitive & Memory Enhancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Limited
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Novartis AG
16.3.4. Eisai Co., Ltd
16.3.5. AbbVie Inc
16.3.6. Johnson & Johnson
16.3.7. Pfizer Inc
16.3.8. Lundbeck A/S
16.3.9. Biogen Inc
16.3.10. Eli Lilly and Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. COGNITIVE & MEMORY ENHANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. COGNITIVE & MEMORY ENHANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. COGNITIVE & MEMORY ENHANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. COGNITIVE & MEMORY ENHANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. COGNITIVE & MEMORY ENHANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. COGNITIVE & MEMORY ENHANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GENERAL COGNITIVE ENHANCEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ANIRACETAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PIRACETAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY ORAL POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 65. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 66. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 67. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 69. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 78. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 118. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 121. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 124. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 128. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 129. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 145. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 147. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 148. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 149. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 156. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 157. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 160. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 190. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 192. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 193. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. DENMARK COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 210. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 211. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 212. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. QATAR COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 218. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 219. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 223. FINLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 246. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 247. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 250. EGYPT COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 253. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 255. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 256. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. TURKEY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 271. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. NORWAY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 282. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 283. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 284. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 286. POLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cognitive & Memory Enhancer Drugs market report include:
  • Teva Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Eisai Co., Ltd
  • AbbVie Inc
  • Johnson & Johnson
  • Pfizer Inc
  • Lundbeck A/S
  • Biogen Inc
  • Eli Lilly and Company

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.26 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cognitive and Memory Enhancer Drugs Market 2025-2033 - Product Image

Cognitive and Memory Enhancer Drugs Market 2025-2033

  • Report
  • 139 Pages
  • Global
From
Memory Enhancement Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Memory Enhancement Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2025 - Product Image

Dementia Associated With Alzheimer's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Dementia Associated with Alzheimer's Disease - Global Strategic Business Report - Product Image

Dementia Associated with Alzheimer's Disease - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Frontotemporal Dementia - Global Strategic Business Report - Product Image

Frontotemporal Dementia - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.